# A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer

Source: https://onco.cc/trials/nct06636435/  
OnCo record `nct06636435` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CBA-1205 run by Chiome Bioscience Inc., now recruiting.

## Summary

A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer is a phase 1 interventional study registered as NCT06636435 by Chiome Bioscience Inc., with 66 participants planned, started 2020-06-01. Conditions recorded: Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma and Pediatric Cancer. Interventions recorded: CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3, CBA-1205 Part 4 and CBA-1205 Part 5.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06636435
- Phase: 1
- Setting: A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors.
- Sponsor: Chiome Bioscience Inc.
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT06636435: https://clinicaltrials.gov/study/NCT06636435

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Melanoma](https://onco.cc/cancers/melanoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [CBA-1205](https://onco.cc/drugs/cba-1205/)
- companies: [Chiome Bioscience](https://onco.cc/companies/chiome-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/nct06636435.json